Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation

Circulation

Volumn 94, Issue 9 SUPPL., 1996, Pages

  Gikakis, Nicolas ^a   Khan, M M H ^b   Hiramatsu, Yugi ^a   Gorman III, J H ^a   Hack, C Eric ^c   Sun, Ling ^b   Rao, A Koneti ^b   Niewiarowski, Stefan ^b   Colman, Robert W ^b   Edmunds Jr , L Henry ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

coagulation; enoxaparin; enzymes; extracorporeal circulation; heparin; thrombosis

Indexed keywords

ADENOSINE DIPHOSPHATE; BETA THROMBOGLOBULIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C5B; ENOXAPARIN; HEPARIN; KALLIKREIN; LEUKOCYTE ELASTASE; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; RECOMBINANT TICK ANTICOAGULANT PEPTIDE; THROMBIN;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; HUMAN; HUMAN TISSUE; LEUKOCYTE ACTIVATION; PRIORITY JOURNAL; SIMULATION; THROMBOCYTE COUNT;

ADENOSINE DIPHOSPHATE; COMPLEMENT ACTIVATION; COMPLEMENT C1 INACTIVATOR PROTEINS; ENOXAPARIN; EXTRACORPOREAL CIRCULATION; FACTOR XA; HUMANS; NEUTROPHIL ACTIVATION; PEPTIDES; RECOMBINANT PROTEINS; THROMBIN;

EID: 10244219864     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Blackstone EH, Kirklin JW, Stewart RW, Chenoweth DE. The damaging effects of cardiopulmonary bypass. In: Wu KK, Roxy EC, eds. Prostaglandins in Clinical Medicine: Cardiovascular and Thrombotic Disorders. Chicago, III: Year Book Medical Publishers Inc; 1982:355-369.
2. Edmunds LH Jr. Why cardiopulmonary bypass makes patients sick: strategies to control the blood synthetic surface interface. In: Karp RB, Laks H, Wechsler AS, eds. Advances in Cardiac Surgery. Chicago, III: Mosby-Year Book Inc; 1995;6:131-167.
3. Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+2. Thromb Haemost. 1993;70: 253-258.
4. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is beparin the ideal anticoagulant? Thromb Haemost. 1993;70:259-262.
5. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
6. Coughlin SR, Vu T-KH, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor. J Clin Invest. 1992;89:351-355.
7. Levin EG, Marzec U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest. 1984;74:1988-1995.
8. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide: a highly selective inhibitor of blood coagulation factor Xa. Science. 1990;248:593-596.
9. Jordan SP, Waxman L, Smith DE, Vlasuk GP. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry. 1990;29:11095-11100.
10. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Co; 1994:837-860.
11. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992; 79:1-17.
12. Lehman ED, Schaefer TF, Przysiecki CT, Joyce JG, Bailey J, Schulman CA. Large-scale purification and characterization of recombinant tick anticoagulant peptide. J Chromatogr B Biomed Appl. 1992; 574:225-235.
13. Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost. 1993;70:212-216.
14. Carvalho ACA, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med. 1974;290:434-438.
15. Rucinski B, Niewiarowski S, James P, Walz DA, Budzynski AZ. Anti-heparin proteins secreted by platelets: purification, characterization and radioimmunoassay. Blood. 1979;53:47-62.
16. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against synthetic peptide. Thromb Haemost. 1991;65:153-159.
17. Amiral J, Walenga JM, Fareed J. Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. Semin Thromb Hemost. 1984;10:228-242.
18. Wachtfogel YT, Kucich U, Greenplate J, Gluszko P, Abrams W, Weinbaum G, Wenger RK, Rucinski B, Niewiarowski S, Edmunds LH, Colman RW. Human neutrophil degranulation during extracorporeal circulation. Blood. 1987;69:324-330.
19. Meri S, Aronen M, Leijala M. Complement activation during cardiopulmonary bypass in children. Complement. 1988;5:46-54.
20. Nuijens JH, Huijbregts CC, Eerenberg BAJ, Abbink JJ, Strack van Schijndel RJ, Felt BRJ, Thijs LG, Hack CE. Quantification of plasma factor XIIa-C1(-)-inhibitor and kallikrein-C1(-)-inhibitor complexes in sepsis. Blood. 1988;72:1841-1848.
21. Hack CE, Hannema AJ, Eerenerg BAJ, Out TA, Aalberse RC. A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo. J Immunol. 1981;127:1450-1453.
22. Mann KG. Prothrombin and thrombin. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Co; 1994: 184-199.
23. Dunwiddie CT, Smith DE, Nutt EM, Vlasuk GP. Anticoagulant effects of the selective factor Xa inhibitors tick anticoagulant peptide and antistasin in the APTT assay are determined by the relative rate of prothrombinase inhibition. Thromb Res. 1991;64:787-794.
24. Keller PM, Schultz LD, Condra C, Karczewski J, Connolly TM. An inhibitor of collagen-stimulated platelet activation from the salivary glands of the Haementeria officinalis leech. J Biol Chem. 1992; 267:6899-6904.
25. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost. 1994;71:314-319.
26. Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem. 1990;265:18289-18297.
27. Seymour JL, Lindquist RN, Dennis MS, Moffat B, Yansura D, Reilly D, Wessinger ME, Lazarus RA. Ecotin is a potent anticoagulant and reversible tight-binding inhibitor of factor Xa. Biochemistry. 1994; 33:3949-3958.
28. Bernabei AF, Rao AK, Niewiarowski S, Colman RW, Sun L, Edmunds LH Jr. Recombinant desulfatohirudin as a substitute for heparin during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994;284:381-382. Brief communication.
29. Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J Clin Invest. 1983; 71:1383-1391.
30. Wachtfogel YT, Kucich U, Hack CE, Niewiarowski S, Colman RW, Edmunds LH Jr. Aprotinin inhibits the contact, neutrophil and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106:1-10.
31. Wachtfogel YT, Hack CE, Nuijens JH, Kettner TM, Reilly TM, Knabb RM, Bischoff R, Tschesche H, Wenzel H, Kucich U, Edmunds LH Jr, Colman RW. Selective inhibitors of kallikrein alter the release of human neutrophil elastase during extracorporeal circulation. Am J Physiology. 1995;268(Heart Circ Physiol 37):H1352-H1357.
32. Sundaram S, Gikakis N, Hack CE, Niewiarowski S, Edmunds LH Jr, Rao AK, Sun L, Cooper SL, Colman RW. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates cellular and humoral activation in simulated extracorporeal circulation. Thromb Haemost. 1996;75:76-82.
33. 358 Arg) inhibits the contact pathway of intrinsic coagulation and alters the release of human neutrophil elastase during simulated extracorporeal circulation. Thromb Haemost. 1994;72: 843-847.
34. Sim R, Arlaud G, Colomb M. Kinetics of reaction of human C1-inhibitor with the human complement proteases C1r and C1s. Biochim Biophys Acta. 1980;612:433-449.
35. Wachtfogel YT, Harpel PC, Edmunds LH Jr, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor and plasmin-alpha 2-plasmin inhibitor complexes during cardiopulmonary bypass. Blood. 1989;73:468-471.
36. Kirklin JK, Chenoweth DE, Naftel DC, Blackstone EH, Kirklin JW, Bitran DD, Curd JG, Reves JG, Samuelson PN. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. Ann Thorac Surg. 1986;41: 193-199.
37. Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparin-induced bleeding by protamine sulfate. Thromb Haemost. 1990;63:271-274.
38. Aiach M, Drefus G, Michaud A, Relland J, Murawski M, Leclerc M, Carpentier A. Low molecular weight (LMW) heparin derivatives in experimental extra-corporeal circulation (ECC). Hemostasis. 1984; 14:325-332.
39. Robitaille D, Leclerc JR, Laberge R, Sahab P, Atkinson S, Cartier R. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg. 1992;103: 597-599.